JPMorgan Initiates Coverage on Dianthus Therapeutics With Overweight Rating
Dianthus Therapeutics (DNTH) has an average rating of buy and mean price target of $139.36, according to analysts polled by FactSet.
6 stories mentioning DNTHUpdated 11d ago
Every FINWIRES story that references DNTH, newest first.
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
Dianthus Therapeutics (DNTH) has an average rating of buy and mean price target of $139.36, according to analysts polled by FactSet.
Dianthus Therapeutics (DNTH) has an average rating of buy and mean price target of $139.36, according to analysts polled by FactSet.
Anne McGeorge, Director, on August 10, 2026, sold 7,750 shares in Dianthus Therapeutics (DNTH) for $844,822.SEC Filing:https://www.sec.gov/Archives/edgar/data/1690585/000177993426000004/xslF345X05/ownership.xml
Adam M Veness, Senior Vice President, General Counsel and Secretary, on August 07, 2026, sold 20,000 shares in Dianthus Therapeutics (DNTH) for $2,208,833.SEC Filing:https://www.sec.gov/Archives/edgar/data/1690585/000177862326000007/xslF345X05/ownership.xml
Dianthus Therapeutics (DNTH) has an average rating of buy and mean price target of $127.64, according to analysts polled by FactSet.Price: $87.50, Change: $-2.74, Percent Change: -3.04%
Ryan Savitz, Executive Vice President, Chief Financial Officer & Chief Business Officer, on April 09, 2026, sold 8,224 shares in Dianthus Therapeutics (DNTH) for $738,844.SEC Filing:https://www.sec.gov/Archives/edgar/data/1690585/000199232426000006/xslF345X05/ownership.xml